Management of Elevated Ferritin in Liver Cirrhosis

Diagnostic Evaluation

• In patients with liver cirrhosis and elevated ferritin, clinicians must first determine whether the elevation reflects true iron overload or an inflammatory response, because ferritin acts as an acute‑phase reactant that can rise independently of iron stores during hepatic necroinflammation. 1
• A transferrin saturation (TSAT) ≥ 45 % together with elevated ferritin strongly suggests true iron overload and should prompt HFE genetic testing for hereditary hemochromatosis. 1
• Chronic liver diseases such as hepatitis C, non‑alcoholic fatty liver disease, and alcoholic liver disease frequently raise ferritin levels without accompanying iron overload. 1
• Necroinflammatory liver disease can produce false‑positive ferritin elevations, underscoring the need for concurrent TSAT assessment. 1

Risk Stratification by Ferritin Level

• In hereditary hemochromatosis, a ferritin level < 1000 µg/L accurately predicts the absence of cirrhosis, allowing clinicians to forgo intensive cirrhosis surveillance in this subgroup. 5
• Among C282Y homozygotes, the combination of ferritin > 1000 µg/L, elevated aminotransferases, and platelet count < 200 ×10⁹/L predicts cirrhosis in approximately 80 % of cases. 1
• When ferritin > 1000 µg/L and TSAT is elevated but HFE mutations are absent, liver biopsy for hepatic iron concentration should be considered to clarify the presence of severe hepatic iron overload. 5

Genetic Testing Strategy

• Any patient with TSAT ≥ 45 % and/or ferritin above the laboratory upper limit of normal should undergo HFE mutation analysis, including both C282Y and H63D testing. 1
• First‑degree relatives of individuals with confirmed hereditary hemochromatosis should be screened for HFE mutations. 5
• C282Y homozygotes with ferritin > 1000 µg/L have a 20‑45 % prevalence of cirrhosis, whereas those with ferritin < 1000 µg/L have a <2 % risk of cirrhosis or bridging fibrosis in the absence of other risk factors. 5
• H63D heterozygotes or homozygotes are generally not at risk for progressive iron overload, while compound heterozygotes (C282Y/H63D) may develop iron overload even with a normal TSAT. [5][1]

Indications and Contraindications for Liver Biopsy

Therapeutic Phlebotomy

• Therapeutic phlebotomy is the preferred treatment for confirmed hereditary hemochromatosis. [4][6]
• During the induction phase, remove 400–500 mL of blood weekly (or every two weeks) while monitoring hemoglobin; discontinue phlebotomy if hemoglobin falls below 11 g/dL. 4
• Target ferritin 50–100 µg/L during induction; during maintenance, aim for ferritin < 200 µg/L in women and < 300 µg/L in men. Avoid ferritin < 20 µg/L to prevent secondary iron deficiency that can increase dietary iron absorption. 4
• Monitor ferritin monthly throughout induction and every six months during maintenance. 4

Surveillance and Lifestyle Recommendations

• Patients with established cirrhosis must continue hepatocellular carcinoma (HCC) surveillance even after successful iron depletion, as HCC accounts for roughly 30 % of hemochromatosis‑related deaths. 6
• Complete abstinence from alcohol is required for cirrhotic patients undergoing iron depletion therapy. 4
• Dietary measures (avoiding iron‑fortified foods, limiting red‑meat intake, and restricting supplemental vitamin C before phlebotomy) are recommended, but they modify iron intake by only 2–4 mg/day and should not replace phlebotomy. 4

Common Pitfalls

• Interpreting an elevated ferritin as iron overload without first checking TSAT can lead to misdiagnosis in the setting of active liver inflammation. 1
• Failing to recognize that ferritin > 1000 µg/L predicts both cirrhosis risk and increased mortality in decompensated patients may delay necessary specialist referral and surveillance. 1